Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genfit S.A. (GNFTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.00000.0000 (0.00%)
At close: 10:31AM EDT
Advertisement
Sign in to post a message.
  • T
    Terminal Gravity
    Stock is sill trading at a 24% discount to cash and gives no value to future payments or royalties or any of their IP. Over time this will correct itself. Accumulating.
    Bullish
  • B
    Brian
    GNFT should be up to $10 on this new deal. It's giving them around $500 million in cash and milestones, and they get 20% of the revenue from the sales of the commercialization. That's a large amount of cash, probably will end up being around $1 billion in cash. Not sure why they only added $2 to the stock price today.
    Bullish
  • Y
    Yahoo Finance Insights
    GNFT is up 17.27% to 4.55
  • A
    Anonymous
    Very quiet board...

    Sometimes, still waters run deep :-)

    Anyone looking at Genfit and elafibranor for the first time (bearing in mind that the Big catalyst is the phase 3 readout in late 2019) might like to know that elafibranor was recently awarded Breakthrough Therapy status in PBC.

    Also, Barclays initiates coverage on 224 at Overweight with a PT of 55 USD (120% upside)
  • A
    Aly
    12/19/2019 Show Full StoriesSend Info

    GNFT09:10 Genfit analyst commentary at Roth Capital 

    Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH. Roth Capital analyst Yasmeen Rahimi said there is an "urgent need" for non-invasive testing in non-alcoholic steatohepatitis, or NASH, and her call with Donna Cryer of the Global Liver Institute, and Dr. Suneil Hosmane, Genfit's EVP and Global Head of Diagnostics, provided a better view into the utility and diagnostic value of the company's NIS4 NIT toolkit, which combines four biomarkers to diagnose fibrosis with high predictability. The analyst, who sees Genfit "unlocking the power of non-invasive NASH diagnosis," keeps a Buy rating and EUR70 price target on the company's shares following her expert call.
  • M
    Mary
    ⭐ Top Bullish Charts | December 2021 💰💵📈

    https://chart-analysis.tools/Bullish-Charts
    Bullish
  • J
    Jason
    Analysts just upgraded with 120% upside

    Check out GNFT Analyst Price Target $11.81 on TipRanks http://www.tipranks.com/ios/pages/stocks/GNFT/price-target
    Bullish
  • G
    Gerald
    I'm long and lonely here. From pre-NASH collapse days. Unusual volume here yesterday and today so far.
  • a
    adf
    Nicolaus analyst Derek Archila has a hold rating on GNFT, arguing that the stock is now likely to remain range bound until management provides an update in the fall for elafibranor in NASH.
    However, there is a glimmer of hope- elafibranor’s program in primary biliary cholangitis (PBC). Archila thinks here GNFT has solid proof-of-concept data from both an efficacy and safety perspective, and that this could provide a floor for shares.
  • p
    placer
    If you're looking for a short and sweet guide to the day's biggest news, I recommend (http://trademarketview.tech). They breakdown the most important pre-market news and it only takes a few minutes to read.
  • h
    hansard
    They had some interesting insights about GNFT on (http://financialdeals.tech). Definitely made me think twice about the company.
  • A
    Anonymous
    See Forbes article today: Is Genfit Primed to Win the NASH Derby?
  • s
    silvia
    120 Euros = $135.6Mil in cash upfront.

    That's $3.30 per share. Stock is only up $2 on the news. Up $3.30, that would have a share price of at the very least, $6.60 per share.

    Add the 28Mil Euro ($31,600,000) investment for 3,985239 shares (or $7.94 per share) and this company should have a share price of at least $6.70.

    Very undervalued here considering the promising future with this deal.
  • T
    Terminal Gravity
    This company is starting to interest me. Recent disappointment but trading below cash. Surely their IP is worth something? Also, technicals are showing an uptick in MFI and MACD just went positive.
  • H
    HADRIAN G
    I'm trying to research this company

    I see A positive article about earnings on April 17 https://finance.yahoo.com/news/why-genfit-gnft-stock-might-124312126.html

    is elafibranor a factor in the earnings from their other operations?

    I'm assuming they will continue to operate in these other areas albeit interrupted by the Pandemic.

    What Say you?
  • A
    Anonymous
    Genfit licenses elafibranor development and commercialization for the Greater China region.

    https://endpts.com/genfit-goes-to-china-with-a-deal-worth-up-to-228m-for-nash-drug/

    (Article complete with amusing analyst commentary that confuses NASH with steatosis)
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
    endpts.com
  • b
    boris
    Genfit: GENFIT ANNOUNCES TRADING HALT OF ITS SHARES AND OF ITS OCEANES ON EURONEXT PARIS AND EURONEXT ACCESS
    www.globenewswire.com
  • T
    Titus
    The company should look into doing a collab work with Galt. A combo therapy for F5-F6. A perfect partnership for NASH awaits and a chance for both to corner all spectrums Fibrosis as a combo therapy.
  • C
    Christophe
    Kepler Cheuvreux 20/2 : "Elafibranor remains the only drug in late stage development that is effective against NASH symptoms, which might make it the backbone therapy for NASH"
  • G
    Gerald
    6 times average volume, up 12.36% on the day and nobody even notices here.
    This is where money big time is about to be made and I have the floor all to myself.
Advertisement
Advertisement